Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Two-Part Study of Nasal NT-301 Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers: a Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Investigation Followed by an Open-Label, Two-Way, Two-Period, Crossover Evaluation of NT-301 Bioavailability Compared to Subcutaneous Apomorphine

NCT06954428 is registered in ClinicalTrials.gov with Nano PharmaSolutions Australia as lead sponsor.

NCT NCT06954428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06954428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Two-Part Study of Nasal NT-301 Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers: a Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Investigation Followed by an Open-Label, Two-Way, Two-Period, Crossover Evaluation of NT-301 Bioavailability Compared to Subcutaneous Apomorphine
Lead sponsor
Nano PharmaSolutions Australia
Phase
Phase 1
Overall status
Completed
Start date
June 20, 2025
Completion date
December 12, 2025
Enrollment
49 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

performance of nt-301 nasal spray device, pharmacokinetics of nt-301 nasal spray, safety of nt-301 nasal spray, tolerability of nt-301 nasal spray